GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE Post author: Post published:May 1, 2026 Post category: Continue ReadingGENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE
Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome Post author: Post published:April 30, 2026 Post category: Continue ReadingPhase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, a gene therapy for Pitt Hopkins Syndrome
Phase I/II Clinical Trial for CMT4J Post author: Post published:April 30, 2026 Post category: Continue ReadingPhase I/II Clinical Trial for CMT4J
Phase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD) Post author: Post published:April 30, 2026 Post category: Continue ReadingPhase 1B/2A study of the safety and tolerability of human neural stem cells for Huntington’s Disease (REGEN4HD)
Inhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy Post author: Post published:April 30, 2026 Post category: Continue ReadingInhibitory Interneuron Cell Therapy (NRTX-1001) for the Treatment of Drug-resistant Bilateral Temporal Lobe Epilepsy
The UCLA Delayed Immunological Tolerance after Kidney Transplantation Program Post author: Post published:April 30, 2026 Post category: Continue ReadingThe UCLA Delayed Immunological Tolerance after Kidney Transplantation Program
RPESC-RPE-4W Therapy for dry Age-related Macular Degeneration Post author: Post published:April 30, 2026 Post category: Continue ReadingRPESC-RPE-4W Therapy for dry Age-related Macular Degeneration
A phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus Post author: Post published:April 30, 2026 Post category: Continue ReadingA phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus
Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A Post author: Post published:April 30, 2026 Post category: Continue ReadingPersonalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A
Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer Post author: Post published:April 30, 2026 Post category: Continue ReadingAutologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer
